Comparative Effectiveness Research/Health Technology Assessment (HTA) Treatment Dynamics of Newly Marketed Drugs and Implications for Comparative Effectiveness Research

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The incident user design in comparative effectiveness research

  2013cited by this paper
• The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction

  2012cited by this paper
• An Event‐Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring

  2012cited by this paper
• Role of disease risk scores in comparative effectiveness research with emerging therapies

  2012cited by this paper
• Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system

  2012cited by this paper
• Active Safety Monitoring of New Medical Products Using Electronic Healthcare Data: Selecting Alerting Rules

  2012cited by this paper
• Implementing the Learning Health System: From Concept to Action

  2012cited by this paper
• Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation

  2012cited by this paper
• Using high‐dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system

  2012cited by this paper
• Design considerations in an active medical product safety monitoring system

  2012cited by this paper
• Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.

  2011cited by this paper
• Availability of comparative efficacy data at the time of drug approval in the United States.

  2011cited by this paper
• How many "me-too" drugs is too many?

  2011cited by this paper
• Antidepressants and Fracture Risk in Older Adults: A Comparative Safety Analysis

  2011cited by this paper
• A combined comorbidity score predicted mortality in elderly patients better than existing scores.

  2011cited by this paper
• Age, Exclusion Criteria, and Generalizability of Randomized Trials Enrolling Kidney Transplant Recipients

  2011cited by this paper
• Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development

  2011cited by this paper
• Validation of claims‐based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially‐insured population

  2010cited by this paper
• Confounder summary scores when comparing the effects of multiple drug exposures

  2010cited by this paper
• Use of disease risk scores in pharmacoepidemiologic studies

  2009cited by this paper
• High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data

  2009cited by this paper
• Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease

  2008cited by this paper
• The prognostic analogue of the propensity score

  2008cited by this paper
• In defense of pharmacoepidemiology--embracing the yin and yang of drug research.

  2007cited by this paper
• Developments in Post‐marketing Comparative Effectiveness Research

  2007cited by this paper
• External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?

  2006cited by this paper
• Research

  2006cited by this paper
• A review of uses of health care utilization databases for epidemiologic research on therapeutics.

  2005cited by this paper
• Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.

  2004cited by this paper
• Evaluating medication effects outside of clinical trials: new-user designs.

  2003cited by this paper
• Validating Administrative Data in Stroke Research

  2002cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Identification of fractures from computerized Medicare files.

  1992cited by this paper
• The exclusion of the elderly and women from clinical trials in acute myocardial infarction.

  1992cited by this paper
• The central role of the propensity score in observational studies for causal effects

  1983cited by this paper

• No citing papers are available for this paper.